Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Our innovative technological approach is to target tumors overexpressing matricellular protein thrombospondin-1 (TSP-1). Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1." title="" class="btn" data-container="body" data-html="true" data-id="173538" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="Apmonia Therapeutics"> 3,093
Activities
Technologies
Entity types
Location
2 Esp. Roland Garros, 51100 Reims, France
Reims
France
Employees
Scale: 2-10
Estimated: 19
SIREN
849959390Engaged corporates
32Added in Motherbase
2 years, 3 months agoApmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies.
Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Our innovative technological approach is to target tumors overexpressing matricellular protein thrombospondin-1 (TSP-1).
Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1.
immunologie and oncologie
Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies.
Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Our innovative technological approach is to target tumors overexpressing matricellular protein thrombospondin-1 (TSP-1).
Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 4 Feb 2025 | | |
![]() J.P. Morgan Bank | J.P. Morgan Bank | Other 1 Jan 2025 | | |
![]() Grand Est Développement, l'Agence régionale des transformations (Grand E-Nov+) Consulting, Business Consulting and Services | Grand Est Développement, l'Agence régionale des transformations (Grand E-Nov+) Consulting, Business Consulting and Services | Other 19 Nov 2024 | | |
![]() Région Grand Est National and local authorities, Government Administration | Région Grand Est National and local authorities, Government Administration | Other 19 Nov 2024 | | |
![]() Maddyness Media, Media Production | Maddyness Media, Media Production | Other 5 Oct 2024 | | |
![]() France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 19 Nov 2024 | | |
![]() Cap Digital Public business cluster, French Cluster, IT Services and IT Consulting | Cap Digital Public business cluster, French Cluster, IT Services and IT Consulting | Other 5 Oct 2024 | | |
![]() | Gouvernement | Other 19 Nov 2024 | | |
![]() | Ministère de la Santé | Other 22 Sep 2024 | | |
![]() Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Other 22 Sep 2024 | |